Ampersand Capital Partners Acquires Nektar Therapeutics' PEG Reagent Manufacturing Business, Launches Gannet BioChem

Gannet BioChem Acquires Laysan Bio

January 22, 2026

Biotechnology

Gannet BioChem, a PE-backed specialty CDMO, has acquired Laysan Bio, a maker of activated polyethylene glycol (PEG) reagents based in Arab, Alabama. The add-on expands Gannet BioChem's activated polymer and bioconjugation capabilities, strengthening its ability to support partners from early development through GMP manufacturing.

Ampersand Capital Partners Acquires Peptides International and Merges It with New England Peptide

December 16, 2019

Biotechnology

Ampersand Capital Partners has acquired Peptides International and merged it into its existing portfolio company, New England Peptide, creating a combined provider of custom and catalog peptide synthesis services. The transaction is an add-on to Ampersand’s New England Peptide platform to expand scale, capabilities, and customer relationships across pharmaceutical, biotech and academic markets.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Vector Laboratories Acquires Quanta BioDesign

June 17, 2023

Biotechnology

Vector Laboratories has acquired Quanta BioDesign, the inventor of discrete polyethylene glycol (dPEG) technology, expanding Vector's bioconjugation linkers, dyes and payload delivery capabilities. The Plain City, Ohio-based company's dPEG reagents will broaden Vector's product portfolio and support life science and biopharma customers in therapeutic, diagnostic and research applications.

Ampersand Capital Partners Majority Recapitalizes Phosphorex

August 25, 2022

Healthcare Services

Ampersand Capital Partners completed a majority recapitalization of Phosphorex to provide growth capital enabling the company to build out a 30,000 sq. ft. facility and establish cGMP manufacturing capabilities for lipid nanoparticles, microspheres and other drug-delivery platforms. The investment positions Phosphorex to expand from development and analytical services into end-to-end CDMO manufacturing to better serve pharmaceutical and biotechnology clients.

Ampersand Capital Partners Makes Growth Investment in VIVEbiotech

December 4, 2024

Biotechnology

Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.